Table 2.
Clinical features of patients treated with mAbs and/or antivirals
| Patient number | Gender, age | Comorbidities | COVID-19 vaccination | Baseline IgG anti-spike protein of SARS-CoV-2 | Current or previous (within 6 months) use of immune-suppressive drugs | Initial COVID-19 therapy (time from symptom onset) | Length of hospitalisation (days) | Subsequent COVID-19 therapies, (time from symptom onset) | Clinical complications | Clinical course and outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F, 60 years | Autoimmune anaemia due to systemic lupus erythematosus | 2 doses of mRNA vaccine | Negative | Rituximab | BAM/ETE (5 days) | 37 days | CAS/IMD and RMD (47 days) |
Respiratory failure Severe anaemia Non-ST-elevation myocardial infarction Secondary depressive syndrome |
Improvement of haemoglobin levels was observed after SARS-CoV-2 RNA negativisation on naso-pharyngeal swab which occurred after 12 days from CAS/IMD and RMD. The patient was subsequently discharged |
| 2 | M, 73 years |
Low-grade non-infiltrating papillary urothelial bladder cancer Type 2 diabetes mellitus hypertension hypercholesterolemia Kidney transplant |
3 doses of mRNA vaccine | Negative |
Mycophenolate mofetil tacrolimus |
SOT (5 days) | 40 days | None |
Severe respiratory failure diarrhoea |
Complications resolved and the patient was discharged continuing low-flow oxygen therapy |
| 3 | M, 38 years | Tetraparesis due to multiple sclerosis | No | Negative | - | SOT (2 days) | 8 days | RMD (6 days) | Severe respiratory failure | Complication resolved and the patient was discharged after 8 days since RMD |
| 4 | M, 56 years |
Severe obesity Type 2 diabetes mellitus Hypertension Non-Hodgkin lymphoma |
2 doses of mRNA vaccine | Negative | Rituximab | RMD (5 days) | 54 days | CAS/IMD (16 days) | Severe respiratory failure | Complication resolved and the patient was discharged after 54 days since CAS/IMD continuing low-flow oxygen therapy |
| 5 | F, 41 years | Burkitt lymphoma | 2 doses of mRNA vaccine | Positive | R-HYPER-C-VAD | SOT and RMD (4 days) | 3 days | None | None | The patient was discharged home soon after SOT and RMD and negativisation of SARS-CoV-2 RNA on naso-pharyngeal swab occurred after 6 days from SOT and RMD |
F female; M male; BAM/ETE bamlanivimab/etesevimab; SOT sotrovimab; RMD remdesivir; CAS/IMD casirivimab/imdevimab; R-HYPER-C-VAD rituximab, cyclophosphamide, vincristine, adriamycin and dexamethasone; mRNA, Messenger RNA.
Patients who received oxygen support by non-invasive ventilation or high-flow nasal cannula were considered to be affected by severe respiratory failure